African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2273

Full Length Research Paper

Evaluating the in silico activity of bioactive compound iressa, tarceva and capsaicin against epidermal growth factor receptor tyrosine kinase

Aristatile Balakrishnan1, Abdullah H. Al-Assaf1, Wajahatullah Khan2, N. Ayyadurai3 and Zainularifeen Abduljaleel4*
1Department of Food Science and Nutrition, College of Food and Agricultural Science, King Saud University, P.O. Box 2460, Riyadh 11451, Saudi Arabia. 2King Faisal University, Riyadh, Saudi Arabia. 3Department of Biotechnology, Central Leather Research Institute (CSIR-CLRI), Chennai, India. 4Umm Al Qura University, Medical Genetics Department, Science and Technology Unit, Mecca, Saudi Arabia.
Email: [email protected]

  •  Accepted: 19 August 2013
  •  Published: 22 September 2013

Abstract

Epidermal growth factor receptor (EGFR) protein tyrosine kinases (PTKs) are known for their role in cancer. Lapatinib drug have been reported to be the molecules of interest, with potent anticancer activity and they act by binding to adenosine triphosphate (ATP) site of protein kinases. ATP binding site of protein kinases provides an extensive opportunity to design newer analogs. Here we aimed to do the molecular docking studies for the potent anti-cancer drugs iressa, tarceva and capsaicin against the breast cancer treatment. The estimated free energy of binding and inhibition constant are highly differed with each drugs compared to the current market available drugs and bioactive compounds. Our results strongly suggest that the bioactive compound capsaicin activity would be comparable with the commercially available cancer drug. Further study indicates that in silico method would be an important tool for the drug design and development against cancer.

 

Key words: Epidermal growth factor receptor (EGFR), inhibitors, docking studies, protein tyrosine kinases (PTKs), breast cancer.